Literature DB >> 23587506

Focal ablation of prostate cancer: four roles for magnetic resonance imaging guidance.

Graham Sommer1, Donna Bouley, Harcharan Gill, Bruce Daniel, Kim Butts Pauly, Chris Diederich.   

Abstract

INTRODUCTION: There is currently a great deal of interest in the possible use of focal therapies for prostate cancer, since such treatments offer the prospect for control or cure of the primary disease with minimal side effects. Many forms of thermal therapy have been proposed for focal ablation of prostate cancer, including laser, high intensity ultrasound and cryotherapy. This review will demonstrate the important roles that magnetic resonance imaging (MRI) guidance can offer to such focal ablation, focusing on the use of high intensity ultrasonic applicators as an example of one promising technique.
MATERIALS AND METHODS: Transurethral and interstitial high intensity ultrasonic applicators, designed specifically for ablation of prostate tissue were tested extensively in vivo in a canine model. The roles of MRI in positioning the devices, monitoring prostate ablation, and depicting ablated tissue were assessed using appropriate MRI sequences.
RESULTS: MRI guidance provides a very effective tool for the positioning of ablative devices in the prostate, and thermal monitoring successfully predicted ablation of prostate tissue when a threshold of 52 ºC was achieved. Contrast enhanced MRI accurately depicted the distribution of ablated prostate tissue, which is resorbed at 30 days.
CONCLUSIONS: Guidance of thermal therapies for focal ablation of prostate cancer will likely prove critically dependent on MRI functioning in four separate roles. Our studies indicate that in three roles: device positioning; thermal monitoring of prostate ablation; and depiction of ablated prostate tissue, MR techniques are highly accurate and likely to be of great benefit in focal prostate cancer ablation. A fourth critical role, identification of cancer within the gland for targeting of thermal therapy, is more problematic at present, but will likely become practical with further technological advances.

Entities:  

Mesh:

Year:  2013        PMID: 23587506      PMCID: PMC4045501     

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  59 in total

1.  Ultrasound applicators for interstitial thermal coagulation.

Authors:  C J Diederich; W H Nau; P R Stauffer
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  1999       Impact factor: 2.725

2.  Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients.

Authors:  Sebastien Crouzet; Xavier Rebillard; Daniel Chevallier; Pascal Rischmann; Gilles Pasticier; Gregory Garcia; Olivier Rouviere; Jean-Yves Chapelon; Albert Gelet
Journal:  Eur Urol       Date:  2010-07-03       Impact factor: 20.096

3.  High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2.

Authors:  Chan Kyo Kim; Byung Kwan Park; Bohyun Kim
Journal:  AJR Am J Roentgenol       Date:  2010-01       Impact factor: 3.959

4.  Transurethral ultrasound applicators with dynamic multi-sector control for prostate thermal therapy: in vivo evaluation under MR guidance.

Authors:  Adam M Kinsey; Chris J Diederich; Viola Rieke; William H Nau; Kim Butts Pauly; Donna Bouley; Graham Sommer
Journal:  Med Phys       Date:  2008-05       Impact factor: 4.071

5.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

Review 6.  Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging.

Authors:  Olivier Rouvière; Rémi Souchon; Rarès Salomir; Albert Gelet; Jean-Yves Chapelon; Denis Lyonnet
Journal:  Eur J Radiol       Date:  2007-08-06       Impact factor: 3.528

7.  Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy.

Authors:  Gary Onik; Winston Barzell
Journal:  Urol Oncol       Date:  2008 Sep-Oct       Impact factor: 3.498

8.  Documenting the location of systematic transrectal ultrasound-guided prostate biopsies: correlation with multi-parametric MRI.

Authors:  Baris Turkbey; Sheng Xu; Jochen Kruecker; Julia Locklin; Yuxi Pang; Vijay Shah; Marcelino Bernardo; Angelo Baccala; Ardeshir Rastinehad; Compton Benjamin; Maria J Merino; Bradford J Wood; Peter L Choyke; Peter A Pinto
Journal:  Cancer Imaging       Date:  2011-03-29       Impact factor: 3.909

9.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Authors:  Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

Review 10.  Focal or subtotal therapy for early stage prostate cancer.

Authors:  J Stephen Jones
Journal:  Curr Treat Options Oncol       Date:  2007-06
View more
  9 in total

1.  Focal point determination in magnetic resonance-guided focused ultrasound using tracking coils.

Authors:  Bryant T Svedin; Michael J Beck; J Rock Hadley; Robb Merrill; Joshua T de Bever; Bradley D Bolster; Allison Payne; Dennis L Parker
Journal:  Magn Reson Med       Date:  2016-07-15       Impact factor: 4.668

Review 2.  Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment.

Authors:  Rachel S Riley; Emily S Day
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-03

Review 3.  Catheter-based ultrasound technology for image-guided thermal therapy: current technology and applications.

Authors:  Vasant A Salgaonkar; Chris J Diederich
Journal:  Int J Hyperthermia       Date:  2015-03-23       Impact factor: 3.914

4.  Correction for Spatial Averaging Artifacts in Hydrophone Measurements of High-Intensity Therapeutic Ultrasound: An Inverse Filter Approach.

Authors:  Keith A Wear; Samuel M Howard
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2019-06-24       Impact factor: 2.725

5.  Evaluation of a three-dimensional MR acoustic radiation force imaging pulse sequence using a novel unbalanced bipolar motion encoding gradient.

Authors:  Joshua T de Bever; Henrik Odéen; Nick Todd; Alexis I Farrer; Dennis L Parker
Journal:  Magn Reson Med       Date:  2015-10-07       Impact factor: 4.668

6.  Drift correction for accurate PRF-shift MR thermometry during mild hyperthermia treatments with MR-HIFU.

Authors:  Chenchen Bing; Robert M Staruch; Matti Tillander; Max O Köhler; Charles Mougenot; Mika Ylihautala; Theodore W Laetsch; Rajiv Chopra
Journal:  Int J Hyperthermia       Date:  2016-05-22       Impact factor: 3.914

Review 7.  MRI-guided biopsies and minimally invasive therapy for prostate cancer.

Authors:  Sangeet Ghai; John Trachtenberg
Journal:  Indian J Urol       Date:  2015 Jul-Sep

8.  Preliminary results of ultrasound-guided laser ablation for unresectable metastases to retroperitoneal and hepatic portal lymph nodes.

Authors:  Yun Mou; Qiyu Zhao; Liyun Zhong; Fen Chen; Tianan Jiang
Journal:  World J Surg Oncol       Date:  2016-06-23       Impact factor: 2.754

9.  MRI-guided, transrectal, intraprostatic steam application as potential focal therapeutic modality for prostatic diseases in a large animal translational model: A feasibility follow-up study.

Authors:  Adriano Wang-Leandro; Florian Willmitzer; Agnieszka Karol; Beat Porcellini; Peter Kronen; Emile M Hiltbrand; Daniel Rüfenacht; Patrick R Kircher; Henning Richter
Journal:  PLoS One       Date:  2019-12-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.